Listen
TALTZ (ixekizumab), immunosuppressive interleukin IL-17A inhibitor
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Jan 26 2017
Reason for request
Inclusion
- TALTZ has Marketing Authorisation in the treatment of moderate to severe plaque psoriasis in adults who require systemic therapy.
- Its superiority to ENBREL (etanercept) and to STELARA (ustekinumab) has been demonstrated, but it has not been compared to COSENTYX (sekukinumab), another IL-17A inhibitor.
- TALTZ should be reserved for the treatment of plaque psoriasis in adults, in patients with severe chronic plaque psoriasis, defined by a failure (insufficient response, contraindication or intolerance) in at least two treatments including nonbiologic systemic treatments and phototherapy AND an extensive form and/or substantial psychosocial impact.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
